Credit Suisse initiated coverage on 23andMe Holding with a new price target
$ME
Biotechnology: Pharmaceutical Preparations
Health Care
Credit Suisse initiated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $13.00